SP 1093VAlternative Names: SP1-Fe306
Latest Information Update: 28 Nov 2007
At a glance
- Originator Supratek Pharma
- Developer Lady Davis Institute for Medical Research; McGill University; Supratek Pharma
- Class Antivirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV-1 infections